dc.contributor.author
Panjideh, Hossein
dc.contributor.author
Niesler, Nicole
dc.contributor.author
Weng, Alexander
dc.contributor.author
Fuchs, Hendrik
dc.date.accessioned
2022-12-30T12:05:36Z
dc.date.available
2022-12-30T12:05:36Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/37370
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-37082
dc.format.extent
2 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
targeted toxins
en
dc.subject
immunotoxins
en
dc.subject
obinutuzumab
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.title
Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
703
dcterms.bibliographicCitation.doi
10.3390/toxins14100703
dcterms.bibliographicCitation.journaltitle
Toxins
dcterms.bibliographicCitation.number
10
dcterms.bibliographicCitation.originalpublishername
MDPI
dcterms.bibliographicCitation.volume
14
dcterms.bibliographicCitation.url
https://doi.org/10.3390/toxins14100703
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie
refubium.note.author
Correction to Toxins 2022, 14(7), 478.
en
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dc.relation.iscorrectionof
https://refubium.fu-berlin.de/handle/fub188/36053
dcterms.isPartOf.eissn
2072-6651
